On March 15, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that the Company’s management team will participate in a virtual presentation at Oppenheimer’s 33rd Annual Healthcare Conference being held March 13-17, 2023 (Press release, Actinium Pharmaceuticals, MAR 15, 2023, View Sourcenews/detail/439/actinium-pharmaceuticals-inc-to-present-at-oppenheimers-33rd-annual-healthcare-conference" target="_blank" title="View Sourcenews/detail/439/actinium-pharmaceuticals-inc-to-present-at-oppenheimers-33rd-annual-healthcare-conference" rel="nofollow">View Source [SID1234628774]). The presentation will include recent Company highlights including positive results from its pivotal Phase 3 SIERRA trial of Iomab-B and development opportunities for Actimab-A under the recently signed Cooperative Research and Development Agreement with the National Cancer Institute (NCI).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information
Date & Time: March 15, 2023, 2:40 PM ET
Webcast Link: View Source

A replay of the presentation will be available on the Company’s IR section of the website for 90 days after the event: View Source

On March 15, 2023 Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will be presenting eight posters on its clinical and preclinical immunotherapies at the AACR (Free AACR Whitepaper) (American Association for Cancer Research) Annual Meeting 2023, which will take place in Orlando, Florida, USA, April 14 – 19 (Press release, Transgene, MAR 15, 2023, View Source [SID1234628704]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters highlight:

✓ the potential of Transgene’s novel cancer vaccines and oncolytic viruses to change the solid tumor treatment landscape in challenging clinical settings, and
✓ the advances that Transgene has made with its two technology platforms.

The details on the upcoming poster presentations are:

TG4050
Title: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

Session title: Late-Breaking Research: Clinical Research 2
Poster and abstract number: LB205
Date and Time: Tuesday April 18, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 20, Section 35
Authors: Ana Lalanne, Camille Jamet, Christian H. Ottensmeier, Jean-Pierre Delord, Christophe Le Tourneau, Matthew S. Block, Gerardo Colon-Otero, Keith L. Knutson, Annette Tavernaro, Gisele Lacoste, Benoit Grellier, Xavier Noiriel, Thierry Huss, Bernard Burtin, Yoshiko Yamashita, Kousuke Onoue, Kazuhide Onoguchi, Brandon Malone, Olivier Lantz, Oliver Baker, Naoko Yamagata, Yuki Tanaka, Eric Quemeneur, Maud Brandely, Kaïdre Bendjama
TG4001
Title: A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers

Session title: Phase II and Phase III Clinical Trials in Progress
Poster and abstract number: CT045
Date and Time: Monday April 17, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 3, Section 46
Authors: Christophe Le Tourneau, Frédéric Rolland, Amaury Daste, Philippe Cassier, Sébastien Salas, Luis Manso Sánchez, Gerardo Colon-Otero, Lauriane Eberst, Olivier Lantz, Ana Lalanne, Annette Tavernaro, Hakim Makhloufi, Kaïdre Bendjama, Maud Brandely, Jean-Pierre Delord.
TG6002
Title: Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

Session title: Phase I Clinical Trials 1
Poster and abstract number: CT190
Date and Time: Tuesday April 18, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 3, Section 46
Authors: Adel Samson, Cristina Smolenschi, Philippe Cassier, Jai V. Patel, Chris Hammond, Marta Kurzawa, Sophie Sainte-Croix, Emma West, Alain Sadoun, Kaidre Bendjama
TG6050
Title: TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

Session title: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies
Poster and abstract number: 694
Date and Time: Sunday Apr 16, 2023; 1:30 p.m. – 5:00 p.m. ET
Location: Board 14, Section 24
Authors: Jean-Baptiste Marchand, Fadi Azar, Christelle Demeusoit, Patricia Kleinpeter, Jules Deforges, Laetitia Fend, Chantal Hoffmann, Huguette Schultz, Nathalie Silvestre, Eric Quéméneur
R&D

Title: Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators.

Session title: Therapeutic Antibodies 1
Poster and abstract number: 1885
Date and Time: Monday April 17, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 24, Section 25
First author: Jean-Baptiste Marchand
Title: Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy

Session title: Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses
Poster and abstract number: 5967
Date and Time: Wednesday April 19, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 28, Section 7
First author: Helene Le
Title: Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

Session title: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory TherapiesPoster and abstract number: 697
Date and Time Sunday Apr 16, 2023; 1:30 p.m. – 5:00 p.m. ET
Location: Board 17, Section 24
First author: Lucas Walther
Title: PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

Session title: Vaccines
Poster and abstract number: 6796
Date and Time: Wednesday Apr 19, 2023; 9:00 a.m. – 12:30 p.m. ET
Location: Board 12, Section 44
First author: Philippe Erbs
In addition to presenting these posters, Transgene will also be hosting a booth during the AACR (Free AACR Whitepaper) congress.

On March 15, 2023 Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, reported that preclinical proof-of-concept data for EO-3021 will be highlighted in an oral presentation at the New Drugs on the Horizon special session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida (Press release, Elevation Oncology, MAR 15, 2023, View Source;utm_medium=rss&utm_campaign=elevation-oncology-to-present-at-the-american-association-of-cancer-research-aacr-annual-meeting-2023 [SID1234628647]). A poster highlighting the preclinical data for EO-3021, a potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, will also be presented at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The oral presentation at this year’s AACR (Free AACR Whitepaper) New Drugs on the Horizon session is an exciting opportunity for Elevation Oncology to showcase preclinical data for EO-3021 as a potential best-in-class ADC targeting solid tumors expressing Claudin 18.2.," said David Dornan, Chief Scientific Officer of Elevation Oncology. "In addition, we look forward to presenting the preclinical data in more detail in a poster session at AACR (Free AACR Whitepaper) and remain on track to initiate a U.S. Phase 1 clinical trial evaluating EO-3021 during the second half of 2023."

Elevation Oncology will also present two posters on NRG1 fusions, including updated data from the Phase 2 CRESTONE study evaluating seribantumab in patients with solid tumors harboring NRG1 fusions. Elevation Oncology announced in January 2023 that it has paused enrollment in the Phase 2 CRESTONE study and further investment in seribantumab, pending entering a partnership.

Details of presentations at AACR (Free AACR Whitepaper) 2023 are as follows:

Title: EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers
Presentation: Oral Presentation by David Dornan, Chief Scientific Officer, Elevation Oncology
Session Type: Drug Development Track: Special Session – New Drugs on the Horizon Session: Part 3
Data and Time: Monday, April 17, 2023, 10:15AM-11:45AM ET

Title: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers
Authors: Mo Dan, et al.
Session Type: Poster Presentation
Session: Experimental and Molecular Therapeutics – Growth Factor Receptors as Therapeutic Targets
Abstract Number: 6300
Data and Time: Wednesday, April 19, 2023, 9:00AM-12:00PM ET

Title: Identification of NRG1 fusions in patients with solid tumors: Analysis from a real-world community oncology network
Authors: Emma G. Sturgill, et al.
Session Type: Poster Presentation
Session: Clinical Research Excluding Trials – Analyses Using Clinical and Genomic Databases
Abstract Number: 921
Data and Time: Sunday, April 16, 2023, 1:30PM-5:00PM ET

Title: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
Authors: Tejas Patil, et al.
Session Type: Poster Presentation
Session: Phase II Clinical Trials 2
Abstract Number: CT229
Data and Time: Tuesday, April 18, 2023, 9:00AM-12:30PM ET

On March 14, 2023 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida (Press release, Erasca, MAR 14, 2023, View Source [SID1234639360]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be available on the AACR (Free AACR Whitepaper) meeting website. The poster will be available online at Erasca.com/science/presentations following the presentation.

Poster Presentation Details

Abstract CT184 – Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: A Phase 1 study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
Date/Time: Tuesday, April 18, 2023, 9:00 AM – 12:30 PM ET
Session: First-in-Human Phase I Clinical Trials 2
Presenter: Dr. Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Location: Orange County Convention Center, Poster Section 45, Poster Board 16

On March 14, 2023 Exscientia plc (Nasdaq: EXAI) reported two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 (‘565), a MALT1 protease inhibitor (Press release, Exscientia, MAR 14, 2023, View Source [SID1234635630]). These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development. IND-enabling studies are underway and the Company expects to provide an update on clinical development plans leveraging Exscientia’s personalised medicine platform in the second half of 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Both molecules were funded through a 2019 collaboration with Celgene, which was acquired by Bristol Myers Squibb, and each molecule met the criteria for which BMS could exercise its option. Bristol Myers Squibb’s options to the candidates have now lapsed and Exscientia maintains all worldwide rights to both compounds. In 2021, an agreement was signed to expand the collaboration to include additional programmes in oncology and immunology. These programmes are currently in active development.

"Building off of our success with the CDK7, A2A and PKC-theta programmes, these candidates clearly show how our AI-driven precision design platform can solve challenging target profiles in a more efficient way than traditional drug discovery," said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. "Both ‘539 and ‘565 met the primary nonclinical design goals for potency, selectivity, dosing and safety. In addition, these molecules also have the potential for meaningful patient selection strategies to optimise clinical design. We are excited about the promise these compounds hold in a broad range of haematologic and solid tumours."

First potent, selective, reversible and brain-penetrant LSD1 inhibitor: EXS74539 (‘539) is a differentiated lysine demethylase 1 (LSD1) inhibitor with potential in both haematology and oncology. LSD1 demethylates histones which play a critical role in regulating the expression of genes which suppress differentiation and drive the proliferation and survival of a number of tumour types. To date, other LSD1 inhibitors in development have failed to achieve the combination of appropriate pharmacokinetics, good brain penetrance and a reversible mechanism of action. Exscientia’s candidate, ‘539, achieves a design objective of suitable CNS penetration to target brain metastases, which are prevalent in certain cancer subtypes. Additionally, in vivo studies of ‘539 have shown favourable activity in small cell lung cancer (SCLC) xenograft models, with dose dependent inhibition of tumour growth. Studies have also shown a favourable absorption, distribution, metabolism, and excretion (ADME) profile, with a shorter predicted human half-life than some LSD1 inhibitors currently in clinical trials. No safety concerns have been observed in preclinical studies conducted to date. Exscientia will present data on the discovery and development of ‘539 at an upcoming scientific conference in the first half of 2023.

Potent and selective MALT1 protease inhibitor with potential safety differentiation: EXS73565 (‘565) is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease inhibitor with potential applications in haematology. MALT1 is a protease crucial for activation of the NF-κB pathway which supports the uncontrolled proliferation of malignant T- and B-cells in haematological cancers. Exscientia’s precision design approach was able to optimise the safety profile for agents targeting MALT1 whilst also generating potency and selectivity. Scaffolds of other MALT1 inhibitors in the clinic significantly inhibit UGT1A1, an enzyme involved in the metabolism of bilirubin, often leading to dose-limiting toxicities in the clinic. In vivo studies of ‘565 have shown anti-tumour activity in mouse models and favourable pharmacokinetics both as monotherapy and in combination with ibrutinib. Toxicology studies have shown that ‘565 has an acceptable therapeutic index, with the ability to maintain high levels of potency, selectivity and safety benchmarks while avoiding meaningful inhibition of UGT1A1, which can lead to hyperbilirubinemia.

"With three existing clinical programmes already in the pipeline, we feel very confident we will meet our goal of four clinical stage compounds in 2024," said Prof. Hopkins. "Our vision is to change the way drug design, discovery and development is done, as we have shown in our first eight drug candidates. Over the course of 2023, we expect to provide more details on these programmes as well as on our broader internal and partnered pipeline."